Table 2.
Clinical characteristics of PCa patients (Cohort 2)a and the correlation with GM+CTCs and total CTCs
| Clinical characteristics | GM+CTCs | Total CTCs | ||||
|---|---|---|---|---|---|---|
| Subgroup | Range | n (Percentage) | P/Nb | P | P/N | P |
| Age (years) | 48–86 | 0.770 | > 0.999 | |||
| ≤ 70 | 27 (50.0%) | 9/18 | 15/12 | |||
| > 70 | 27 (50.0%) | 8/19 | 15/12 | |||
| Gleason score | 6–9 | 0.099 | 0.013* | |||
| ≤ 7 | 28 (51.9%) | 6/22 | 11/17 | |||
| ≥ 8 | 26 (48.1%) | 11/15 | 19/7 | |||
| Clinical Stage | NA | 0.003* | < 0.001* | |||
| I + II | 24 (44.4%) | 2/22 | 7/17 | |||
| III + IV | 30 (55.6%) | 15/15 | 23/7 | |||
| Metastasis | NA | 0.002* | 0.007* | |||
| No | 25 (46.3%) | 2/23 | 9/16 | |||
| Yes | 29 (53.7%) | 15/14 | 21/8 | |||
| tPSA (ng/mL) | 0.01–6000.0 | 0.003* | 0.017* | |||
| ≤ 20 | 24 (44.4%) | 2/22 | 9/15 | |||
| > 20 | 30 (55.6%) | 15/15 | 21/9 | |||
| fPSA/tPSA | 2.24–50.68 | 0.965 | 0.322 | |||
| ≤ 15% | 32 (59.3%) | 10/22 | 16/16 | |||
| > 15% | 22 (40.7%) | 7/15 | 14/8 | |||
| ALP (U/L) | 44–718 | 0.200 | 0.808 | |||
| ≤ 90 | 26 (48.1%) | 6/20 | 14/12 | |||
| > 90 | 28 (51.9%) | 11/17 | 16/12 | |||
| Hb (g/L) | 71–162 | 0.507 | 0.625 | |||
| ≤ 120 | 25 (46.3%) | 9/16 | 13/12 | |||
| > 120 | 29 (53.7%) | 8/21 | 17/12 | |||
*P < 0.05
aCohort 2 includes 54 patients pathologically diagnosed with prostate cancer
bP: positive; N: negative. The positive criterion of CTCs test is ≥3/5 mL